Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome

Trial Profile

A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Sapacitabine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 28 Oct 2018 Planned primary completion date changed from 1 Nov 2011 to 1 Dec 2018.
    • 21 Apr 2015 Status changed from recruiting to active, no longer recruiting as per M.D. Anderson Cancer Center.
    • 10 Dec 2013 Interim results for the cohort of elderly patients with hypomethylating agent-refractory MDS presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top